Lisurid

Lisurid
(IUPAC) ime
	1,1-Diethyl-3-(7-metil-4,6,6a,7,8,9-heksahidro-indolo[4,3-fg]hinolin-9-il)-ureja
Klinički podaci
AHFS/Drugs.com	Internacionalno ime leka
Identifikatori
CAS broj	18016-80-3
ATC kod	G02CB02 N02CA07
PubChem	28864
DrugBank	DB00589
ChemSpider	26847
UNII	E0QN3D755O
KEGG	D08132
ChEBI	CHEBI:51164
ChEMBL	CHEMBL157138
Hemijski podaci
Formula	C20H26N4O
Mol. masa	338,447 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C20H26N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,10-11,14,18,21H,4-5,9,12H2,1-3H3,(H,22,25)/t14-,18+/m0/s1 ; Key: BKRGVLQUQGGVSM-KBXCAEBGSA-N
Farmakokinetički podaci
Bioraspoloživost	10-20% za lisurid vodonik maleat
Vezivanje za proteine plazme	oko 15%
Metabolizam	Hepatički
Poluvreme eliminacije	2 sata
Izlučivanje	renalno i bilijarno u jednakim količinama
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	Samo na recept
Način primene	Oralno, supkutano, transdermalno

Verzija za štampanje više nije podržana i može davati greške. Podnovite oznake i koristite ugrađenu mogućnost štampanja preglednika.

Lisurid (Dopergin, Proclacam, Revanil) je antiparkinsonski agens iz izo-ergolinske klase. On je hemijski srodan sa dopaminergičnim ergolinskim lekom za Parkinsonovu bolest.

Lisurid se se koristi za snižavanje prolaktina i, u niskim dozama, za sprečavanje migrenskih napada. Smatra se da upotreba lisurida kao inicijalnog antiparkinsonskog tretmana može da produži period tokom kojeg nije neophodno da se koristi levodopa. Preliminarna ispitivanja sugerišu da dermalna primena lisurida može da bude korisna u lečenju Parkinsonove bolesti. Lisurid se veoma slabo apsorbuje pri oralnoj promeni i ima kratak poluživot, te produžena transdermalna primena ima znatnu prednost.

Mod dejstva

Lisurid je parcijalni agonist dopaminskog i serotoninskog receptora. On ima visok afinitet za dopaminske D2, D3 i D4 receptore, kao i za serotoninske 5-HT1A^[6] i 5-HT2A/C receptore.^[7] Dok lisurid ima sličan profil vezivanja za receptore kao i bolje poznati i hemijski sličan ergoloid N,N-dietil-lisergamid (LSD), on nema psihodelne efekte.^[8]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Marona-Lewicka D, Kurrasch-Orbaugh DM, Selken JR, Cumbay MG, Lisnicchia JG, Nichols DE (October 2002). „Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats”. Psychopharmacology (Berl.) 164 (1): 93–107. DOI:10.1007/s00213-002-1141-z. PMID 12373423.
↑ Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M (April 1998). „Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors”. Psychopharmacology (Berl.) 136 (4): 409–14. DOI:10.1007/s002130050585. PMID 9600588.
↑ González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA (February 2007). „Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior”. Neuron 53 (3): 439–52. DOI:10.1016/j.neuron.2007.01.008. PMID 17270739.

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[pmid12373423-6] Marona-Lewicka D, Kurrasch-Orbaugh DM, Selken JR, Cumbay MG, Lisnicchia JG, Nichols DE (October 2002). „Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats”. Psychopharmacology (Berl.) 164 (1): 93–107. DOI:10.1007/s00213-002-1141-z. PMID 12373423.

[pmid9600588-7] Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M (April 1998). „Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors”. Psychopharmacology (Berl.) 136 (4): 409–14. DOI:10.1007/s002130050585. PMID 9600588.

[pmid17270739-8] González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA (February 2007). „Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior”. Neuron 53 (3): 439–52. DOI:10.1016/j.neuron.2007.01.008. PMID 17270739.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]